Lacerta Bio is a business development consultancy specializing in identifying, assessing, negotiating, and closing licensing and partnership opportunities for the pharmaceutical, biotechnology, and drug delivery industries.
We also work with and support internal business development teams with market research, competitive intelligence, financial modeling, and other support services.
If you need assistance finding or assessing business development and/or partnership opportunities, contact us at firstname.lastname@example.org.
Lacerta Bio is seeking both parenteral and ophthalmic (topical) products for in-licensing on behalf of a US-based client. Key criteria are: > Products which can be developed via the 505(b)(2) regulatory process in the US > No specific therapeutic area or indication > Injectable could be infusion, prefilled syringe, or related presentation > Ophthalmics areRead More»
Our client has a Preclinical, highly selective mTOR 1/2 inhibitor available for licensing. This compound is a truly selective inhibitor of both mTORC1 and mTORC2, without PI3K activity or toxicity. With an excellent projected safety profile & oral administration, a number of indications within and outside oncology are possible. For more information, contact us via email by clicking on the linkRead More»
Our European client has developed a series of novel, patented salt forms of the most popular NSAIDS on the market (ibuprofen, naproxen, etc.). Clinical data demonstrates three important properties of these new compounds: Enhanced Safety – In multiple clinical studies, our client has shown that these novel salt forms have lower rates of severeRead More»
We believe this is unsustainable, as employee direct and associated costs are a major portion of healthcare spending.
Depending on your point of view, this trend is ripe for disruption and value creation, or under threat of attack from technologies.
But which ones? And in which areas? Here are a few:
Distribution & Logistics: Online retailers are absolute masters of product sourcing, logistics, and distribution. Check out this video on Amazon’s Robots for an example…very few employees in sight:
Drug warehouses are no different. Their application of robotics and automation is just as impressive.
However, our industry will continue to push this trend of replacing employees with robots and computers.
How long will it be before drug products are robotically loaded onto self-driving cars and trucks, and delivered directly to pharmacies for patient receipt?
Or flown via drone directly to patients’ homes?
The technology is here already. It’s perhaps a question of time, investment, and regulatory change.
Blockchain – When most people hear “blockchain,” they think cryptocurrency, like BitCoin.
However. the underlying distributed blockchain database paradigm can be applied to any series of transactions.
Medical records is an obvious place where the application of blockchain can increase efficiency and security. Indeed, there is no reason why, in 2018, we should be filling out paper forms and making photocopies of insurance cards whenever we visit a new physician.
Regulatory filings could be processed much more quickly using blockchain. Imagine an FDA approval in a few days after an NDA submission?
How many FDA employees wold pay the price for this?
Artificial Intelligence – Here is a term which gets batted around quite a bit in our industry. Defining it and its many applications is a challenge. However, what is abundantly clear is that machine learning and decision margin has the potential to accelerate drug discovery and development.
Indeed, combining all three of these categories would do wonders for drug development, accelerating clinical trials, accelerating regulatory processes, and saving money.
It’s the “saving money” bit that important when looking at it from a labor perspective. What does “saving money” mean?
Two things…first, the investment that is not made, i.e., due to an early tox signal, is an investment that can be made in another area.
But second, it also means the employees who are replaced by all of these robots and blockchains and smart machines…machines who do not have to eat, pay mortgages, or save for retirement.
One problem with all of this is the sheer size and complexity of our healthcare system. Thus, this process will likely proceed very slowly. Indeed, Amazon’s potential entry into drug distribution is a relative small step in the entire value chain.
However, where there is complexity and overhead, there will be companies with automation and software solutions which reduce costs and accelerate transactions.
It’s happened in retail and other sectors, and healthcare will not be any different.
Deloitte recently published their annual report on returns generated by big pharma from their R&D investments. The PDF report is available here. The report is divided into two sections. The first is an analysis of data from “12 large cap companies,” and focused on R&D spending and sales. The report is generally well written,
As a pharmaceutical scientist, the concept of “synthetic biology” sounds somewhat oxymoronic. It’s true that our industry has been manipulating genes and cells to produce peptides, proteins, and other drugs/intermediates for decades. But how about creating a cell line to make leather? Or clothing? Or building insulation? Synthetic biology makes these ideas possible. The
What did we find interesting about 2017? What will happen in 2018? Our brief video summarizes our thoughts on the year that’s coming to a close, and also discusses what to keep an eye on in 2018.